Amgen Inc. (AMGN) has seen mixed trading, with shares acquired by several firms including
Verity & Verity LLC, Calamos Wealth Management LLC, Hofer & Associates. Inc, and SS&H Financial Advisors Inc., while others like
Miracle Mile Advisors LLC and Alpine Woods Capital Investors LLC sold their holdings. With a
strong growth outlook for 2026, this pharmaceutical giant continues its innovation stride, highlighted by the recent
FDA expansion of UPLIZNA for Generalized Myasthenia Gravis. It is important to note the financial performance of the company, with the
third quarter financial results of 2025 already announced. However, analysts are divided in their opinions. With
Morgan Stanley and BMO Capital tending to trim price targets, Goldman Sachs and others anticipate strong price appreciation.
HSBC has turned more bullish on Amgen (AMGN), further exemplifying this divide. Amid these dynamics, the company remains committed to improving affordability of medicines in the U.S., through partnerships with government. The Amgen's new drug MariTide continues showing strength, despite mixed data at ADA Conference. Among their accomplishments is a $650M expansion of U.S Manufacturing indicating a rise in production capacity.
Amgen AMGN News Analytics from Fri, 18 Jul 2025 07:00:00 GMT to Sat, 03 Jan 2026 14:41:37 GMT -
Rating 5
- Innovation 4
- Information 6
- Rumor 5
